Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (AKBA) closed a senior secured term loan facility with Symbiotic Capital worth up to $140 million on November 12, 2026. The initial $60.0 million tranche was fully funded at closing, and Akebia used its proceeds to repay in full its $55.0 million BlackRock loan facility. Akebia can request up to an additional $80.0 million, which Symbiotic Capital may fund at its discretion.
The facility has a 60-month maturity and a 60-month interest-only period, with principal due at maturity. It bears a variable monthly interest rate equal to the greater of WSJ Prime plus 4.5% or 11.5%. Akebia reaffirmed its cash runway guidance of at least two years. Additional loan agreement details are scheduled for a Form 8-K filing with the SEC on November 16, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointInitial $60.0 million tranche was fully funded at closing. 46% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Additional financing of up to $80.0 million may be requested. 61% of market cap
- Minor pointBlackRock's $55.0 million loan facility was repaid in full using initial tranche proceeds.
- Minor point60-month interest-only period defers principal payments until maturity.
- Minor point. Forward-looking: it has not happened yet and may not happen.Akebia reaffirmed cash runway guidance of at least two years.
Negative
- Major pointNew senior secured debt bears variable monthly interest at the greater of WSJ Prime plus 4.5% or 11.5%.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Additional up to $80.0 million remains subject to Symbiotic Capital's funding discretion. 61% of market cap
Key Figures
- Initial loan tranche
- $60.0 million
- Fully funded at closing
- Additional loan financing
- up to $80.0 million
- Symbiotic Capital may fund at its discretion
- Repaid BlackRock loan
- $55.0 million
- Repaid in full using initial tranche proceeds
- Loan maturity
- 60 months
- Principal due at maturity
- Interest-only period
- 60 months
- Principal due at maturity
- Interest rate
- Greater of WSJ Prime plus 4.5% or 11.5%
- Variable monthly interest rate
- Cash runway guidance
- at least two years
- Reaffirmed by Akebia
Historical Context
-
Q3 report cited planned term-loan refinancing as part of funding the operating plan for at least two years.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
senior secured term loan facility financial
interest-only financial
form 8-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initial
Incremental tranche of up to
WALTHAM, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has entered into a senior secured term loan facility with Symbiotic Capital (the “Symbiotic Loan Facility”). The Symbiotic Loan Facility consists of an initial tranche of
The Symbiotic Loan Facility closed on November 12, 2026. Akebia used the proceeds from the initial tranche to repay in full its
“We are very pleased to announce this financing which enhances our operational flexibility and gives us the potential to access additional non-dilutive capital to advance our strategic initiatives. Today we also reaffirm our cash runway guidance of at least two years,” said Erik Ostrowski, Akebia’s Chief Financial and Chief Business Officer. “We are excited to partner with Symbiotic Capital, whose deep expertise in healthcare financing makes them an ideal collaborator. We are also very appreciative of our partnership with BlackRock over the past several years.”
“Akebia has a portfolio of revenue-generating products and a pipeline focused on kidney disease, led by a management team with deep experience in the space,” said Chris York, Senior Managing Director at Symbiotic Capital. “We are pleased to provide this financing and look forward to supporting Akebia as it executes on its business strategy.”
Additional details of the loan agreement will be provided in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission (SEC) on November 16, 2026.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
About Symbiotic Capital
Symbiotic Capital is a healthcare credit platform that brings together decades of experience across healthcare, finance, and entrepreneurship. Its integration into a global healthcare ecosystem empowers it to provide lending solutions to fuel the growth of established healthcare companies around the world.
Forward-Looking Statements
Statements in this press release regarding Akebia Therapeutics, Inc.'s (“Akebia's”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: the potential for Akebia to access up to an additional
The terms “intend,” “believe,” “designed,” “plan,” “goal,” “potential,” “anticipate,” “estimate,” “target,” “predict,” “expect,” “future,” “may,” “will,” “could,” “continue,” derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the potential therapeutic benefits, safety profile and effectiveness of Akebia's products and product candidates; risks and uncertainties related to Akebia's ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials, and the timing of such preclinical studies and clinical trials; the results of Akebia's preclinical studies and clinical trials, including that initial, preliminary, interim, or topline results do not necessarily predict final results and remain subject to final verification that may result in the final data being materially different from the initial data previously published; preclinical, clinical or retrospective data, analyses or results may not be replicated in, or predictive of, results of future preclinical or clinical data, analyses or results or that such analyses or results may not support further development of such product candidates; Akebia's ability to initiate and enroll patients in its clinical trials; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to Akebia's commercial products, including estimates regarding the potential market opportunity; the competitive landscape for Akebia's commercial products, including generic entrants and the timing thereof; Akebia's ability to obtain and maintain patent protection on its products and product candidates, and to successfully defend these patents against third-party challenges; Akebia's ability to attract and retain qualified personnel; Akebia's ability to achieve and maintain profitability and to maintain operating expenses consistent with its operating plan; Akebia's revenue and that its financial results from prior periods may not be indicative of future results; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; early termination of any of Akebia's collaborations; and changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs. Other risks and uncertainties include those identified under the heading “Risk Factors” in Akebia's most recent Quarterly Report on Form 10-Q filed with the SEC, and other filings that Akebia may make with the SEC in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.
Akebia Therapeutics® and Vafseo® are registered trademarks of Akebia Therapeutics, Inc. and its affiliates.
Akebia Therapeutic Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much financing did Akebia secure from Symbiotic Capital?
Akebia closed a facility worth up to $140 million, including $60.0 million fully funded at closing. It can request up to an additional $80.0 million, but Symbiotic Capital may fund that amount at its discretion.
What are the interest rate and repayment terms of Akebia's Symbiotic loan?
The loan bears a variable monthly interest rate equal to the greater of WSJ Prime plus 4.5% or 11.5%. It has a 60-month maturity and a 60-month interest-only period, with principal due at maturity.